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Because bradykinin constitutes a possible candidate 
for mediation of topical 8-methoxypsoralen-UV A-
(PUV A)-induced erythema, aprotinin (Trasylol), inhibi-
tor of kallikrein and interrupter of the cascade leading 
to kinin production was assessed in guinea pigs. Re-
Sponse was assessed at 24, 48, and 72 hr after topical 
PUV A and there was no significant difference between 
normal saline and aprotinin by intradermal or intraper-
itoneal routes of administration. The results of this study 
indicate that intradermal and intraperitoneal aprotinin, 
in the dose and method tested, is not capable of signifi-
cantly decreasing erythema induced by topical PUV A in 
guinea pigs. 
Indomethacin has been shown to be capable of inhibiting 
DVB-induced erythema in guinea pigs and humans [1,2]. This 
finding is significant in that prostaglandins can be implicated 
as ITlediators of DVB-induced erythema. Erythema produced 
by DVB radiation and that produced by UV A after administra-
tion of psoralen (PUV A) are dissimilar in that the latter has a 
significantly later onset and peaks at approximately 48 hr. 
Neither topical, intradermal or oral indomethacin is capable of 
diminishing the inflammatory response produced by PUV A 
[3]. Therefore, it is probable that substances other than pros-
taglandin are mediators of this inflammation. 
Bradykinin, a nona peptide, is a vasoactive mediator in some 
inflammatory reactions. Plasma kinin is derived from the alpha 
globulin, kininogen, by activation of plasma kallikrein. Simi-
larly, tissue kallidin is formed from a tissue kininogen which is 
converted to the active kinin by cleavage of its N-terminal 
lysine. Kallikrein is itself converted from its zymogen, prekal-
Iikrein, by the Hageman Factor or a fragment thereof. 
Kinins have been associated with arteriolar vasodilation and 
increased vascular permeability, as well as with increased leu-
kotaxis and contraction of smooth muscle. Dose for dose, brady-
kinin has been shown to be more potent as a vasodilator than 
either PGE, or PGE2 when injected intradermally into guinea 
pigs and rabbits [4,5], while PGF, and PGF2 are less potent. 
Since a major histological change in the dermis of PUV A-
treated skin is increased permeability and vasodilation of su-
perficial blood vessels [6], bradykinin constitutes a possible 
candidate for mediator of the reaction, 
Aprotinin (Trasylol) is a 6,511 MW, 58 amino acid peptide 
dimer derived from bovine lung. Available as 10,000 kallidogen-
ase inactivating units per ml, it is capable of inhibiting the 
action of a number of proteolytic enzymes, including kallikrein, 
and thus interrupts the cascade leading to kinin production 
[7]. It has been primarily studied as an antitrypsin agent in 
acute pancreatitis, but its anti-inflammatory properties have 
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also been investigated with some success in treatment of ana-
phylaxis [8], osteoarthritis [9], chronic urticaria [10], and acne 
[11]. It has been shown to reduce rat paw edema induced by 
subaponeurotic kaolin injections in rats [12], to inhibit the 
Schwartzman phenomenon in rabbits [13] and to inhibit inflam-
mation secondary to experimental burns in rats [13]. 
For these reasons, we felt it would be of interest to investigate 
the ability of aprotinin to inhibit the erythema induced by 
topical PUV A. 
MATERIALS AND METHODS 
Ultraviolet Irradiation 
Two Westinghouse F15T8 BLB 40 w bulbs were used as the energy 
source and mounted in a standard desk top fluorescent fixture covered 
with aluminum foil. The BLB bulb has a blue filter tube which emits 
radiation between 310 and 420 nm with an emission peak at 355 nm. 
The UV A output of the bulbs, as measured by an International Light, 
Model 1U42 radiometer, was 5.2 mw/ cm2 at 2 cm below the bulb 
surface. The UVB output, measured by an International Light, Model 
lL700 radiometer, was 2p.w/ cm2 at the same distance (UVB < 0.39% of 
UVA). 
Prepa.ration of Animals 
Sixteen male, short hair, albino guinea pigs were used in the study. 
Each animal was 6-7 mo old and weighed an average of 650 gm (532-
752 gm). The dorsal surface of each animal was clipped and depilated 
with calcium hydroxide, sodium thioglycolate and calcium thioglycolate 
cream (Nair, Carter Products) and then thoroughly rinsed and dried. 
After waiting 24 hr to minimize the effect of any occult tissue irritation, 
2 mg of 8-methoxypsoralen (8MOP) was dissolved in 3 ml of 95% ethyl 
alcohol and evenly distributed over a 4 X 10 cm area. Two hours later, 
a UVA sunscreen (2-ethoxy-ethyl p-methoxycinnamate 4% and men-
thyl anthralinate 4% cream, Maxafil, Texas Pharmacal Co.) was evenly 
applied to all exposed skin except for 2 rows of three 1 X 1.75 cm areas. 
The areas were symmetrically placed 0.5 cm from either side of the 
spine. The animals were immediately placed in thin, chicken-wire cages 
so that their backs were 2 cm beneath the surface of the bulbs. They 
were then exposed to light as described. 
Determination of the MPD 
The minimal phototoxic dose (MPD) is defined as the minimal 
amount of UVA radiation, given 2 hr after 8MOP, required to produce 
erythema with definite margins at 48 hr. In order to determine the 
MPD, 2 animals were prepared as described above. Five areas on each 
animal were exposed to 2-10 J /cm2 of UVA at increments of 2 J /cm2. 
After determining the MPD, the response at the other sites was graded 
as follows: 0 = no detectable erythema, 1+ = erythema only, 2+ = 
erythema plus edema, 3+ = erythema plus vesiculation, 4+ = necrosis. 
The 6th area on each animal was not exposed to UV A light to insure 
that nothing in the preparation of the animals was, by itself, capable of 
producing erythema, Also, a third guinea pig was exposed to UVA light 
without 8MOP for a period of time equivalent to 2 X MPD of the 2 
animals treated with both 8MOP and light. 
Intra.dermal Aprotinin 
Five guinea pigs were prepared as described above. Immediately 
prior to irradiation, 1 row of 3 exposure sites was injected intradermally 
with 1,000 units (0.1 ml) of aprotinin. The 3 adjacent areas were injected 
with 0.1 ml of normal saline control. The peau d'orange produced in 
each case covered approximately 3/ 4 of the exposure area. Each animal 
was then positioned under the fluorescent bulbs and exposed to 2 X 
MPD. Four of the 6 sites were reinjected at 2 hr postexposure and 2 of 
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these 4 sites were reinjected at 24 hr postexposure. Response was 
graded from 0-4+ at 24, 48 and 72 hr. 
J ntraperitoneal Aprotinin 
Six animals were depilated and treated with 8MOP and Maxafil as 
before except that the dorsal surfaces were divided longitudinally along 
the spine so that only half the area was used at a time. One hour before 
exposing the animals to UV A light, each received 0.65 ml of normal 
saline control intraperitoneally. They were reinjected at 2 and 24 hr 
postexposure. The response was rated as before at 24, 48 and 72 hr. 
Once these determinations were made, the other halves of the 
animals' skins were prepared and 6,500 units (0.65 ml) of aprotinin 
(10,000 units/kg/dose) was injected one hour prior to and 2 and 24 hr 
following UV A exposure. The response was rated at 24, 48 and 72 hr. 
A 7th animal underwent the procedure for intraperitoneal aprotinin 
but received 2 ml of normal saline and 20,000 units (2 ml) of aprotinin 
(30,800 uni ts/kg/dose) at appropriate in tervals instead of the previous 
6,500 units (0.65 ml). In addition to the 2 and 24 hr reinjection times, 
the animal was also injected at 12 and 36 hr at the increased dose. 
RESULTS 
The responses produced at the different sites on the guinea 
pigs' backs at 24, 48 and 72 hr after intradermal or intraperito-
neal injection with normal saline versus aprotinin were evalu-
ated (see the Figure). A visible response was produced at all 
exposure sites at 48 hr, but no statistically significant difference 
was found between the sites injected with aprotinin and those 
injected with normal saline.' In addition, there was no signifi-
cant difference at 24 and 72 hr, suggesting that the time course 
of the erythema production was unaffected by aprotinin.· The 
2 animals treated with 8MOP and no UV A light and the one 
animal treated with UV A light and no 8MOP showed no 
erythema. 
DISCUSSION 
The results of this study indicate that aprotinin, in the dose 
and method tested, is not capable of significantly decreasing 
the erythema induced by UVA radiation after topical8MOP in 
guinea pigs. Also, exposure to the radiation source without 
8MOP produced no response at any of the 6 sites on one guinea 
pig and substantiated that the 2 p.w of UVB from the radiation 
source was not a factor in the production of erythema. Likewise, 
topical 8MOP alone did not induce erythema. 
Aprotinin has a rather short serum half-life of 150 min [14]. 
It is possible that the drug was not present at an effective level 
at the proper moment to inhibit erythema. However, when the 
dose and frequency of injection were increased in 1 animal 
receiving intraperitoneal aprotinin, there was no additional 
reduction in erythema. 
The inability of aprotinin to significantly inhibit PUV A-in-
duced erythema does not entirely rule out kinins as a partici-
pant in the inflammatory response because nonspecific kinino-
genases, such as plasmin and trypsin, can bypass the kallikrein 
system entirely in converting kininogen ~o bradykinin. It· is 
possible that an unidentified protease exists locally, which is 
not affected by aprotinin. 
There IS much evidence to support the interaction of kinins 
with other chemical mediators such as histamine, prostaglandin 
and serotiriin in producing inflammation. Bradykinin has been 
shown , to release histamine, a potent vasodilator, from mast 
cells in vitro [15). Prostaglandin is thought to be an indirect 
mediator of the action of bradykinin in vasodilation and sys-
temic hypotension '[16]. Prostaglandins 'potentiate bradykinin-
induced vascular permeability [17,18] as well as its nociceptive 
effect [19]. Also, bradykinin will cause significant swelling in rat 
paws within the rust 30 min after injectiol}. However, its effect 
becomes ' insignificant when given in combination with PGEI 
and '~erotonin [20). , . 
Thus, it is conceivaplt; that a combination of vasoactive 
.chemicals mediates PUV A-induced erythema. Histamine, ser-
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Comparison data of responses at paired sites in guinea pigs with 
aprotinin and 8MOP versus normal saline and 8MOP (mean values are 
shown with mean ± SD). 
otonin, heparin and SRS-A are of interest since mast cell 
degranulation has been seen after exposure to 8MOP and long-
wave ultraviolet light [6]. Specifically, pretreatment of white 
pigs with the histamine receptor antagonists pyrilamine (HI) or 
cimetidine (Hz) had no effect in blocking the photobiologic 
increase in blood content (erythema) but showed a significant 
dose related inhibition of the increased permeability to albumin 
(vascular permeability) [21]. The serotonin receptor antagonist 
methysergide had the same effects but was about 10 times more 
active [21]. In addition, lymphokines may playa key role in the 
inflammatory process because the onset is delayed and UV A 
i.rradiation results in the perivascular accumulation of lympho-
cytes after 48 hr [22]. 
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